NCCN upgraded support to category 2A for BCG-unresponsive high-grade papillary Ta/T1 without CIS, while maintaining category ...
Stocktwits on MSN
IBRX stock rises premarket as founder flags early Anktiva immune data — Macau nod fuels bull case
Executive chairman Patrick Soon-Shiong highlighted early immune activation data from an Anktiva study. ・Anktiva was also ...
Stocktwits on MSN
IBRX stock set to snap 2 weeks in red: Anktiva joins global blockbusters on Macau drug list
The therapy also gained momentum in the U.S. after NCCN added it as a treatment option for papillary bladder cancer patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results